Telomere biology disorders

Telomere biology disorders are rare inherited conditions, the best known being dyskeratosis congenita, in which faulty telomere-maintenance genes make the protective caps on the chromosome ends shorten far too fast. Tissues that depend on constant renewal fail early, above all the bone marrow, and the lungs scar. They are the clearest human proof that telomere maintenance matters for health.

If lung scarring (pulmonary fibrosis) runs in your family, or you have unexplained bone-marrow failure, ask a specialist about genetic testing and the clinical-grade telomere test (flow-FISH). A diagnosis changes how other organs are monitored.

What goes wrong

Telomeres are stretches of repetitive DNA that cap the ends of each chromosome and shorten a little with every cell division; the biology is on Telomere attrition. In dyskeratosis congenita and related telomere biology disorders, inherited mutations in telomere-maintenance genes cause the caps to shorten far too fast.

The classic signs, though not everyone has them, are abnormal nails, lacy skin discolouration and white patches in the mouth. Patients face an increased risk of bone-marrow failure, scarring of the lungs (pulmonary fibrosis), blood cancers, and head-and-neck or anogenital cancers.[1] Bone-marrow failure develops in more than 80% of cases of dyskeratosis congenita.[2]

Why they matter for aging

These conditions are, in effect, accelerated aging localised to the tissues that divide most. They are a human natural experiment confirming that when telomeres go, the tissues that depend on constant renewal go first. That is stronger evidence than any association study of telomere length in the general population, and it is why the descriptive biology of telomere loss is considered well established.

Who should be tested

Testing matters for people with lung scarring that runs in the family, or with unexplained bone-marrow failure. In adults, faulty telomere maintenance is the most common single-gene cause of inherited lung fibrosis,[3] and faults in telomere genes turn up in roughly 3 in 10 families affected by it.[4] For these patients a specialist genetic diagnosis matters, because the condition can affect other organs that need monitoring or treatment.[5]

The right test is flow-FISH (flow cytometry with fluorescence in situ hybridisation), a cell-by-cell fluorescence technique and the only telomere test validated for diagnosing these diseases.[6] The cheap kits sold to consumers, based on the polymerase chain reaction (PCR), miss many borderline cases; the comparison is on Telomere length test.

Danazol: a telomere drug tested in these patients

Danazol, a synthetic male hormone, improved blood counts in about four in five patients with telomere-driven marrow failure, and the trial's PCR measurements suggested telomeres even lengthened.[7] On longer follow-up, though, the benefit faded once the drug stopped, and in the few patients retested with the more accurate flow-FISH method, telomeres held steady rather than lengthening.[8]

In telomere-related lung scarring it was poorly tolerated: fewer than half of patients completed a year of treatment, and side effects alone made more than a third stop.[9]

It is a specialist treatment for a rare disease, not an anti-aging drug.

What to do

  1. Know the warning pattern: pulmonary fibrosis in more than one relative, or unexplained bone-marrow failure.
  2. Ask for specialist genetic testing and flow-FISH, not a consumer telomere kit.
  3. Don't read danazol's results as a reason to take it for aging. As a telomere treatment it has been tested only in these disorders, and its benefit faded once it stopped.

Further reading

  • Savage SA, Niewisch MR. Dyskeratosis Congenita and Related Telomere Biology Disorders. GeneReviews (updated 2023).[10]
  • Bowden AR, et al. Familial pulmonary fibrosis: a UK consensus framework for the investigation and management of patients and their relatives. Thorax 2026.[11]
  • Townsley DM, et al. Danazol Treatment for Telomere Diseases. N Engl J Med 2016.[12]
  • Lee NC, et al. Danazol treatment for telomere biology disorders: long-term results of a phase 1/2 study. Blood Adv 2026.[13]
  • Sicre de Fontbrune F, et al. Efficacy and safety of danazol for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation. ERJ Open Res 2026.[14]
  • Franke M, et al. Diagnosis and management of adult telomere biology disorders. Haematologica 2026.[15]
— § —